Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact

Clinical Pathways

Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact
June 17, 2025
Guest User
FDA shares FAQs on IRBs

06/17/2025

-

In February 2025 the US Food and Drug Administration (FDA) posted a series of frequently asked questions (FAQ) on their website from the public regarding Institutional Review Boards (IRB) and the protection of human subjects in research.

FDA shares FAQs on IRBs
June 3, 2025
Guest User
Final Guidance Released on IRB Written ...

06/03/2025

-

In February 2025, the US Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) Office for Human Research Protection (OHRP) released the final guidance “Institutional Review Board (IRB) Written Procedures.”

Final Guidance Released on IRB Written Procedures
May 30, 2025
Guest User
Now Available: Clinical Pathways’ Major Changes ...

05/30/2025

-

In the ever changing world of clinical research, staying up to date with the latest guidelines and best practices is crucial. Our Major Changes in GCP from ICH E6(R2) to (R3): Road Map is designed for busy professionals who want to deepen their knowledge on GCP to help ensure they meet the highest standards of quality, safety, and compliance.

May 21, 2025
Guest User
FDA Draft Guidance on Considerations for AI Use

05/21/2025

-

In January 2025, the US Food and Drug Administration (FDA) published a draft guidance titled “Considerations for the Use of Artificial Intelligence (AI) to Support Regulatory Decision-Making for Drug and Biological Products” for trial sponsors and stakeholders intending to use AI to generate data and clinical evidence.

FDA Draft Guidance on Considerations for AI Use
April 30, 2025
Guest User
EMA on the use of Real-World Data/Evidence in ...

04/30/2025

-

In March, 2025, the European Medicines Agency (EMA) released a “Reflection paper on use of real-world data (RWD) in non-interventional studies (NIS) to generate real-world evidence (RWE) for regulatory purposes” as a guidance for stakeholders on quality planning, conduct and analysis of NISs that intend to use RWD to generate RWE.

EMA on the use of Real-World Data/Evidence in Non-Interventional Studies
Sandra Sather
July 18, 2014

Finding Balance

Sandra Sather
July 18, 2014

07/18/2014

Check out the Key Note Corner for iiBig!

Sandra Sather
July 18, 2014

NEW FDA Draft Guidance on Informed Consent JULY 2014

Sandra Sather
July 18, 2014

07/18/2014

Tomorrow, July 24th, join us for an Informed Consent (IC) discussion that includes the new FDA IC Information Sheet, released last week. Please join us at 1pm EST.

Sandra Sather
July 2, 2014

Informed Consent

Sandra Sather
July 2, 2014

07/02/2014

Changes to the Declaration of Helsinki /DoH...the interpretations of the 2013 changes related to IC are being debated related to who can obtain consent; can this be delegated vs. required to include or IC signed off by the PI?

Sandra Sather
June 26, 2014

Root Cause Analysis Opportunities for GCP

Sandra Sather
June 26, 2014

06/26/2014

Root cause analysis (RCA) is an important process that is not inherent and involves scientific principles. Tools used to perform RCA (e.g. 5 Whys, fishbone diagrams, cause mapping, force field analysis, etc.) do not teach an individual how to perform RCA.

Sandra Sather
June 9, 2014

RBM: Round Table Discussion

Sandra Sather
June 9, 2014

06/09/2014

There are many opportunities where root cause analysis (RCA) can be used in running clinical trials, but not just for non-compliance root cause assessment. Another important opportunity to use root cause analysis is in an anticipatory environment.

Newer Posts
Older Posts
 
Archive List
  • 2013 6
  • 2014 31
  • 2015 25
  • 2016 21
  • 2017 31
  • 2018 55
  • 2019 56
  • 2020 63
  • 2021 50
  • 2022 39
  • 2023 27
  • 2024 25
  • 2025 18

Subscribe to Blogs and Newsletters.

By signing up, you agree to our our Privacy Policy. You may unsubscribe from emails at any time.

Thank you! You will receive a confirmation email shortly.

Back to Top
Clinical Pathwaysinfo@clinicalpathwaysresearch.com

Cookie Notice | License Agreement | Privacy Policy | Return Policy | Terms and Conditions | Data Security Policy | Confidentiality Policy

© 2025 Clinical Pathways. All rights reserved.